CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 283 enrolled
Drug / intervention
Tranexamic Acid Injectable Solution +1 moredrug
Likely dose
Tranexamic Acid Injectable Solution 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03923959
NCT03923959Phase 3Completed

Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion

Lancaster General Hospital·interventional·Posted Apr 23, 2019·Updated Oct 10, 2024

In Brief

A Phase 3 clinical trial evaluating Tranexamic Acid Injectable Solution and Placebo for Hip Fractures. Completed, enrolled 283 participants across 1 site.

Detailed Summary

The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fractures
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 23, 2019
Enrollment StartFeb 1, 2020
Primary CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.2 years ago

Interventions

Tranexamic Acid Injectable Solutiondrug

100 cc normal saline mixed with 1g of tranexamic acid in solution

Placeboother

100 cc normal saline